Hodgkin lymphoma (HL) is one of the most curable pediatric and adult cancers, with long-
term survival rates now exceeding 90% after treatment with chemotherapy alone or …

Hematologic cancers in pediatric, adolescent, and young adult populations include a
diverse spectrum of malignancies. The cornerstone of treatment is multiagent chemotherapy …

Purpose The Children's Oncology Group study AHOD0031, a randomized phase III study,
was designed to evaluate the role of early chemotherapy response in tailoring subsequent …

Background: Survivors of childhood cancer are at risk for secondary breast cancer. Other
than previous chest radiation therapy, risk factors for secondary breast cancer have not been …

Context More than 90% of children with favorable-risk Hodgkin lymphoma can achieve long-
term survival, yet many will experience toxic effects from radiation therapy. Pediatric …

Purpose To evaluate the outcome of pediatric patients with refractory or relapsed Hodgkin's
disease (HD) who undergo high-dose therapy and autologous hematopoietic stem-cell …

Historically, both adult and childhood Hodgkin lymphoma (HL) were treated with full-dose
(35-45 Gy) extended-field radiation therapy (RT). Although this treatment was the first to …

Purpose To evaluate the efficacy of vinblastine, doxorubicin, methotrexate, and prednisone
(VAMP) and cyclophosphamide, vincristine, and procarbazine (COP) chemotherapy and …

Background Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by
computed tomography (CT) and/or positron emission tomography (PET) after two to three …

Hodgkin lymphoma (HL) accounts for 5% to 6% of all childhood cancer. It displays
characteristic epidemiological, clinical, and pathological features according to various …